<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DDD14154-81FB-417E-81AA-AAEA066ECA04"><gtr:id>DDD14154-81FB-417E-81AA-AAEA066ECA04</gtr:id><gtr:name>The Wellcome Trust  Sanger Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:postCode>CB10 1SA</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339"><gtr:id>EF6B1E83-9BAD-4ED0-B2A0-5E1A69687339</gtr:id><gtr:name>European Commission</gtr:name><gtr:address><gtr:line1>Wetstraat 200 / Rue de la Loi 200</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/664FA0A0-B6F5-431F-AA4E-4D5070BAD879"><gtr:id>664FA0A0-B6F5-431F-AA4E-4D5070BAD879</gtr:id><gtr:firstName>Kholoud</gtr:firstName><gtr:surname>Porter</gtr:surname><gtr:orcidId>0000-0002-9226-6206</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UU_12023%2F15"><gtr:id>47465AA2-515D-45D3-B67E-E80DBE382D71</gtr:id><gtr:title>HIV Epidemiology.</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UU_12023/15</gtr:grantReference><gtr:abstractText>This is mainly a programme of studies following up adults and children with HIV and fits in well with the clinical trials programme. This is because these studies can highlight areas where more investigative studies like clinical trials need to be done. They are also important in helping statisticians to design these trials and allow us to follow people up over the longer term to see how they do beyond the time that they re in the clinical trials.||The observational studies in adults are the UK Register of HIV Seroconverters, which led to a bigger collaboration called CASCADE funded by the European Commission, and which the UK Register is now part of. CASCADE was first funded in 1997 and brings together experts conducting 23 studies in 15 European countries, Australia and Canada. The studies have one thing in common in that they are of HIV infected people for whom we have a reasonably accurate date of when they became infected, or seroconverted. Information from these seroconverters allow us to follow-up people who ve recently become infected throughout the whole period since they came in contact with the virus.||A study in children called CHIPS (Collaborative HIV Paediatric Study) was established in April 2000, and follows-up HIV infected children in the UK and Ireland. CHIPS is a collaboration between centres caring for HIV-infected children, many of whom are enrolled in PENTA trials (the Paediatric European Network for the Treatment of AIDS), the National Study of HIV in Pregnancy and Childhood (NSHPC) at the Institute of Child Health, and the MRC CTU. The main objectives of CHIPS are to describe clinical, laboratory and treatment data for these children, as well as their use of paediatric HIV services. CHIPS aims to enhance the exchange of information and expertise between centres in order to promote standardised high quality paediatrician-led care of all HIV-infected children in the UK and Ireland.||The UK HIV Drug Resistance Database is a central repository for resistance tests performed as part of routine clinical care throughout the UK. Established in 2001, by the end of 2007 over 51,000 test results have been received and stored. A key feature of the Database is extensive patient-level linkage with several clinical cohorts and surveillance databases in the UK. This has allowed analyses which have given important insights into the epidemiology and clinical aspects of HIV drug resistance.||Evidence for Action (EfA) is a five-year international research programme funded from the UK Department for International Development. EfA focuses on HIV treatment and care systems and the goal of the research programme is to contribute to knowledge on how to design, manage and deliver comprehensive HIV treatment and care programmes in resource-poor settings. The programme will provide evidence-informed, practical recommendations to policy makers, programme managers and funding agencies on how to maximise the benefits and equity of HIV treatment &amp;amp; care systems in developing countries.</gtr:abstractText><gtr:technicalSummary>The HIV epidemiology programme largely comprises cohort studies and cohort collaborations, in adults and children, and complements the clinical trials programme. These observational studies raise questions which may then be answered by trials and are a necessary resource for trial design and sample size calculations. They also contribute to the assessment of long-term outcomes.||In adults, the UK Register of HIV Seroconverters has formed the basis for an HIV cohort collaboration (CASCADE), first established in 1997 and maintained through several successful EU funding bids, between the investigators of 23 cohorts of persons with well-estimated dates of HIV seroconversion (~20,000 seroconverters). It is currently a network of epidemiologists, statisticians, virologists and clinicians from lead HIV institutions in 15 European countries, Australia and Canada. Seroconverters are enrolled into the individual cohorts locally and nationally and are typically followed up life-long. CASCADEs main aim is to monitor newly infected individuals and those already enrolled in studies, covering the entire duration of HIV infection. The main premise is that through pooling data issues can be addressed, which cannot be reliably addressed from single studies alone.||In children, The Collaborative HIV Paediatric Study (CHIPS) was established in April 2000, and is a multi-centre cohort study of HIV infected children in the UK and Ireland. CHIPS is a collaboration between centres caring for HIV-infected children, many of whom are enrolled in PENTA trials (the Paediatric European Network for the Treatment of AIDS), the National Study of HIV in Pregnancy and Childhood (NSHPC) at the Institute of Child Health, and the MRC CTU. The main objectives of CHIPS are to describe clinical, laboratory and treatment data for these children, as well as their use of paediatric HIV services. CHIPS aims to enhance the exchange of information and expertise between centres in order to promote standardised high quality paediatrician-led care of all HIV-infected children in the UK and Ireland.||The UK HIV Drug Resistance Database is a central repository for resistance tests performed as part of routine clinical care throughout the UK. Established in 2001, by the end of 2008 over 51,000 test results have been received and stored. Most of these (around 90%) are in the form of viral gene sequences. A key feature of the Database is extensive patient-level linkage with several clinical cohorts and surveillance databases in the UK. This has allowed analyses which have given important insights into the epidemiology and clinical aspects of HIV drug resistance.||Evidence for Action (EfA) is a five-year international research programme with core funding from the UK Department for International Development. EfA focuses on HIV treatment and care systems and the goal of the research programme is to contribute to knowledge on how to design, manage and deliver comprehensive HIV treatment and care programmes in resource poor settings. The programme will provide evidence-informed, practical recommendations to policy makers, programme managers and funding agencies on how to maximise the benefits and equity of HIV treatment &amp;amp; care systems in developing countries.</gtr:technicalSummary><gtr:fund><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-08-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>779000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Experimental Medicine Division</gtr:department><gtr:description>HEATHER</gtr:description><gtr:id>B1CA1C58-2C35-4AA5-99F3-8D5E44959041</gtr:id><gtr:impact>none yet</gtr:impact><gtr:outcomeId>5452705dec55a6.00718868-1</gtr:outcomeId><gtr:partnerContribution>Clinical follow-up, measuring HIV reservoir, analysis</gtr:partnerContribution><gtr:piContribution>Design of study, idenifying eligible patients, design of database, analysis</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Commission</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:description>EuroCoord</gtr:description><gtr:id>499E2BA1-C26A-403E-B2A4-4D6C970F5159</gtr:id><gtr:impact>the network was multidisciplinary being made up of clinicians, public health specialists, epidemiologists, statisticians, bioinformaticians, virologists
&amp;gt;100 publications arose from EuroCoord many of which contributed to HIV treatment guidelines- these are listed here http://www.eurocoord.net/publications_and_presentations
no systematic information was kept of postgraduate thesis arising from EuroCoord but the data contributed to &amp;gt;10 PhDs and ~5 MSc projects, 2 of whom were on MRC studentships</gtr:impact><gtr:outcomeId>58c29d84cb8b76.17239728-1</gtr:outcomeId><gtr:partnerContribution>EuroCoord is made up of 25 beneficiaries from 16 countries to ensure representativeness across Europe. The nature of the collaboration means that apart from these partners, there is also an associated network of numerous affiliated sites - more than 100 collaborating centres, or third parties. The tasks of EuroCoord are organised into 15 different workpackages, all of which are interrelated, and unified through the scientific oversight workpackage.
The overarching aim of EuroCoord is to use the scientific strengths of each collaboration to ensure that the best, most competitive research is performed. Such a large, integrated network has allowed a common virtual database to be established, which currently has access to data from &amp;gt; 300,000 HIV-infected individuals from many different settings across Europe and beyond. EuroCoord's multidisciplinary approach allows the following key areas of HIV research to be addressed, aimed at improving the management and life of HIV-infected individuals, whilst allowing us to explore differences within sub-groups:
Characterising HIV infected populations in Europe (including the epidemiology of different subtypes)
Improving our understanding of pathogenesis (including understanding the mechanisms of non-progression)
Documenting uptake of and response to therapy
Evaluating the implications of long-term HIV infection and exposure to therapy
Assessing the implications of specific management strategies
Improving the management of hepatitis co-infection
Tuberculosis (TB) among HIV-infected patients
HIV and AIDS in migrant populations in Europe
Modelling the HIV infected population in Europe.
The Network also established training programmes to improve research skills, e.g. statistical techniques to allow researchers to undertake observational research of the highest caliber, basic and updated laboratory and clinical training to aid the management of HIV-infected patients.</gtr:partnerContribution><gtr:piContribution>I was the Principal Investigator for EuroCoord, an EU-funded Network of Excellence of HIV cohort studies. The network was managed by my team. Although I was specifically responsible for 2 of the 15 workpackages the aims of which were to provide the framework within which to conduct and analyse data from HIV seroconverters by:
Pooling and enlarging the datasets available for analyses to address pre-specified objectives and future questions arising in the lifetime of the project
Implementing a harmonisation process for the collection of key socio-economic variables (in collaboration with WP14)
Establishing the infrastructure and know-how to estimate HIV incidence in Central &amp;amp; Eastern European countries. 
The WPs also aim to characterise newly-acquired HIV infection, its contribution to the epidemic, and to assess outcome and its determinants in individuals with early diagnosis, focussing on:
Applying techniques which distinguish recent from chronic HIV infection and testing populations
Assessing the outcome of infected individuals following infection
Identifying differences in disease progression
Determining viral and host genetic factors and their relevance to outcome.
As project Leader, I had overall responsibility for all 15 workpackages</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Wellcome Trust Sanger Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>HGC</gtr:description><gtr:id>49C8B159-ADAB-434B-B1E7-02104E901D3C</gtr:id><gtr:impact>A systematic review of definitions of extreme phenotypes of HIV control and progression. Gurdasani D, Iles L, Dillon DG, Young EH, Olson AD, Naranbhai V, Fidler S, Gkrania-Klotsas E, Post FA, Kellam P, Porter K, Sandhu MS. AIDS. 2014 Jan 14;28(2):149-62. doi: 10.1097/QAD.0000000000000049. Review.

An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, Chaix ML, Amornkul P, Babiker A, Sandhu MS, Porter K; CASCADE Collaboration in EuroCoord. PLoS One. 2014 Jan 28;9(1):e86719. doi: 10.1371/journal.pone.0086719. eCollection 2014.</gtr:impact><gtr:outcomeId>54526baaa2abe6.26132401-1</gtr:outcomeId><gtr:partnerContribution>Provided funding for sequencing and the expertise to undertake the appropriate analyses</gtr:partnerContribution><gtr:piContribution>Phenotype defitions were based on my team's work on evaluation of various definitions. The UK Register, for which I'm PI, had already amassed data and samples from eligible individuals- making it possible for the project to achieve objectives and meet deadlines</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Section of Endocrinology and Investigative Medicine</gtr:department><gtr:description>BEEHIVE</gtr:description><gtr:id>A55C67E1-475B-4DD7-BDB6-C6F898ABF859</gtr:id><gtr:impact>None yet</gtr:impact><gtr:outcomeId>54526e268c43e5.64794881-1</gtr:outcomeId><gtr:partnerContribution>Whole genome sequencing of HIV from individuals samples at the time of their viral set point</gtr:partnerContribution><gtr:piContribution>Provided data and samples from HIV seroconverters</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>C78A6F96-196E-46F4-8A7B-E21E12955944</gtr:id><gtr:title>Temporal trends in prognostic markers of HIV-1 virulence and transmissibility: an observational cohort study.</gtr:title><gtr:parentPublicationTitle>The lancet. HIV</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8352078ca98c41558105c7dc74704bb4"><gtr:id>8352078ca98c41558105c7dc74704bb4</gtr:id><gtr:otherNames>Pantazis N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2352-3018</gtr:issn><gtr:outcomeId>56b1c98ce4ba59.03866681</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F7EC68FD-26CF-4005-B938-D96DA63E5F6A</gtr:id><gtr:title>Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68ef4bc924b19c7e189b6f654810964e"><gtr:id>68ef4bc924b19c7e189b6f654810964e</gtr:id><gtr:otherNames>Doyle T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>58c297c520c3e3.82957462</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>512E1B0A-96B3-4CF2-91FC-2CE12F4D6A19</gtr:id><gtr:title>Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/538dc621cb901e80c1188bb06941ac87"><gtr:id>538dc621cb901e80c1188bb06941ac87</gtr:id><gtr:otherNames>De Luca A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>pm_13071_21_23315324</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3444137-B276-4613-B1E9-6214CD272D4F</gtr:id><gtr:title>Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3bb7550f609baa2a9b35e3e68f3c7c7"><gtr:id>d3bb7550f609baa2a9b35e3e68f3c7c7</gtr:id><gtr:otherNames>Lodi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>5a941166e7b8f7.22155504</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>00DF817B-8DBF-4C53-97AA-9AD864859923</gtr:id><gtr:title>The Art of HIV Elimination: Past and Present Science.</gtr:title><gtr:parentPublicationTitle>Journal of AIDS &amp; clinical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f5f47d17f8ccd876f774a4d5dca372e8"><gtr:id>f5f47d17f8ccd876f774a4d5dca372e8</gtr:id><gtr:otherNames>Iwuji CC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>58c2959c9997a7.96300400</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>935016DB-C628-4859-94E6-6714134B711A</gtr:id><gtr:title>A global survey of HIV-positive people's attitudes towards cure research.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/48b41a7bf26cc5bdd6192b93f1e3b8e5"><gtr:id>48b41a7bf26cc5bdd6192b93f1e3b8e5</gtr:id><gtr:otherNames>Simmons R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>58c2959d651ea8.41271406</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89AFE586-451B-4BB1-9AAF-909A1A621E9A</gtr:id><gtr:title>Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5bd1f740adf1f1d53054cf906ed72378"><gtr:id>5bd1f740adf1f1d53054cf906ed72378</gtr:id><gtr:otherNames>Jose S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>58c297c56cf266.16840768</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>14A2AEC2-9F9A-4B62-A793-140D11792664</gtr:id><gtr:title>Limiting Cumulative HIV Viremia Copy-Years by Early Treatment Reduces Risk of AIDS and Death.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ffadb08aae12c5867ce7c13b7fc78833"><gtr:id>ffadb08aae12c5867ce7c13b7fc78833</gtr:id><gtr:otherNames>Olson AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>58c2959ccc95a3.83025144</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0305A258-F6ED-45A8-84F5-397950FD0422</gtr:id><gtr:title>Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21753c19115a53fc66f6c862b5fa4c1a"><gtr:id>21753c19115a53fc66f6c862b5fa4c1a</gtr:id><gtr:otherNames>AIDS-defining Cancer Project Working Group for IeDEA and COHERE in EuroCoord</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>5a940e911cf593.23476710</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6180B3B-AF00-4AFA-A0C3-09366254566D</gtr:id><gtr:title>CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a90b45f679d889fd75b95b5af0f57380"><gtr:id>a90b45f679d889fd75b95b5af0f57380</gtr:id><gtr:otherNames>Wittkop L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>5a94116502eef6.70282936</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41A08A31-CDCD-4279-8D84-67FEBACA43DF</gtr:id><gtr:title>Correction: Viral genetic variation accounts for a third of variability in HIV-1 set-point viral load in Europe.</gtr:title><gtr:parentPublicationTitle>PLoS biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0351bae3aa5dfd63500c2a34e3a65992"><gtr:id>0351bae3aa5dfd63500c2a34e3a65992</gtr:id><gtr:otherNames>Blanquart F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1544-9173</gtr:issn><gtr:outcomeId>5a941165e8f884.62000109</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A9AC567C-D46B-4C06-A7BF-1215C958E0CF</gtr:id><gtr:title>From HIV infection to therapeutic response: a population-based longitudinal HIV cascade-of-care study in KwaZulu-Natal, South Africa.</gtr:title><gtr:parentPublicationTitle>The lancet. HIV</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/283d71ddef0f3fe3408fb71fec23393f"><gtr:id>283d71ddef0f3fe3408fb71fec23393f</gtr:id><gtr:otherNames>Haber N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2352-3018</gtr:issn><gtr:outcomeId>58c2959de6d1c1.11112686</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B34FE56-40F0-466A-BC1F-66741FA7F65E</gtr:id><gtr:title>An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2280b53b8ea89e614bf096b707df6238"><gtr:id>2280b53b8ea89e614bf096b707df6238</gtr:id><gtr:otherNames>Smit E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>5a940e92676043.58346520</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7CCD750F-A3F8-4E87-A318-BF596CFBF0FD</gtr:id><gtr:title>Symptomatic illness and low CD4 cell count at HIV seroconversion as markers of severe primary HIV infection.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3bb7550f609baa2a9b35e3e68f3c7c7"><gtr:id>d3bb7550f609baa2a9b35e3e68f3c7c7</gtr:id><gtr:otherNames>Lodi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>544e2957c429b9.80125565</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42803E7D-11B7-422E-863C-F2A1923461A8</gtr:id><gtr:title>Lack of decline in hepatitis C virus incidence among HIV-positive men who have sex with men during 1990-2014.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/520617cfd9a16fd58acfe534a3534651"><gtr:id>520617cfd9a16fd58acfe534a3534651</gtr:id><gtr:otherNames>van Santen DK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>5a94116451a3f7.33047086</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1E46BF6-8D83-4B71-AA04-11700575F890</gtr:id><gtr:title>Post-treatment control or treated controllers? Viral remission in treated and untreated primary HIV infection.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef922613a50f9dbe25b1e6f369d66d77"><gtr:id>ef922613a50f9dbe25b1e6f369d66d77</gtr:id><gtr:otherNames>Martin GE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5a9411639e7582.81056607</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3AB9E3A9-E0CE-4AD8-B329-97585151B6E8</gtr:id><gtr:title>Evaluating the Impact of Functional Genetic Variation on HIV-1 Control.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/43a34d5ba4672eb405936834c07b1b47"><gtr:id>43a34d5ba4672eb405936834c07b1b47</gtr:id><gtr:otherNames>McLaren PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>5a94116748cab8.73437970</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B027E6CC-0DF6-4B6C-9239-B1C47E030DFF</gtr:id><gtr:title>HIV-1 subtype and virological response to antiretroviral therapy: a confirmatory analysis.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9859179eab8d2f5d7df659dae68e5864"><gtr:id>9859179eab8d2f5d7df659dae68e5864</gtr:id><gtr:otherNames>Dolling DI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>pm_13071_21_23074305</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ECC6062C-D01C-4F96-B52E-0B1A5CC51DAC</gtr:id><gtr:title>Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1816521cf70493060b185b80207903df"><gtr:id>1816521cf70493060b185b80207903df</gtr:id><gtr:otherNames>Judd A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>58c297c285b4d7.57914590</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4F9FE8D-458E-4DA5-8EC5-FD997C95CE7E</gtr:id><gtr:title>Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/061981b83e8b7d1055ec8ea525737650"><gtr:id>061981b83e8b7d1055ec8ea525737650</gtr:id><gtr:otherNames>Jarrin I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>56c5b7cbc9e5f3.48924682</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9351109F-5C40-4A68-BE1A-E4D4DAAB0289</gtr:id><gtr:title>Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/538dc621cb901e80c1188bb06941ac87"><gtr:id>538dc621cb901e80c1188bb06941ac87</gtr:id><gtr:otherNames>De Luca A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>58c297c37a1a89.19600891</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7508247D-CE3E-4248-BE6F-8327A28D31DA</gtr:id><gtr:title>CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7324b8af6edb8e5c0da29ec499df3ad2"><gtr:id>7324b8af6edb8e5c0da29ec499df3ad2</gtr:id><gtr:otherNames>Ghosn J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>5a9411671f9690.86085378</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ED72EB24-A64B-4F42-B9AB-3CBB7B00F23C</gtr:id><gtr:title>Evidence of Self-Sustaining Drug Resistant HIV-1 Lineages Among Untreated Patients in the United Kingdom.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c364bb47d84d53cfc830c1a911aa5fdf"><gtr:id>c364bb47d84d53cfc830c1a911aa5fdf</gtr:id><gtr:otherNames>Mbisa JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>58c297c5e21c54.15750199</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>880482F4-1EAE-4360-9405-4721148EC54B</gtr:id><gtr:title>Transmission of Non-B HIV Subtypes in the United Kingdom Is Increasingly Driven by Large Non-Heterosexual Transmission Clusters.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e26fd1d275edccf846e4efd533484ad"><gtr:id>5e26fd1d275edccf846e4efd533484ad</gtr:id><gtr:otherNames>Ragonnet-Cronin M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>58c297c3e56967.44377176</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5797A38F-E312-43B6-8F7B-2D02196BFF94</gtr:id><gtr:title>High percentage of recent HIV infection leading to onward transmission in Odessa, Ukraine associated with young adults.</gtr:title><gtr:parentPublicationTitle>AIDS and behavior</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/48b41a7bf26cc5bdd6192b93f1e3b8e5"><gtr:id>48b41a7bf26cc5bdd6192b93f1e3b8e5</gtr:id><gtr:otherNames>Simmons R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1090-7165</gtr:issn><gtr:outcomeId>pm_13071_21_23686153</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1E15301-23C9-4372-80A5-C08078FF5F62</gtr:id><gtr:title>Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study.</gtr:title><gtr:parentPublicationTitle>The lancet. HIV</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91e9e79ddc1ff12466df8f0af4fb3c40"><gtr:id>91e9e79ddc1ff12466df8f0af4fb3c40</gtr:id><gtr:otherNames>Caniglia EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2352-3018</gtr:issn><gtr:outcomeId>5a941164758f30.05367402</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9116346-9B17-4D1F-A73B-18DBC7696144</gtr:id><gtr:title>Constructing the cascade of HIV care: methods for measurement.</gtr:title><gtr:parentPublicationTitle>Current opinion in HIV and AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/283d71ddef0f3fe3408fb71fec23393f"><gtr:id>283d71ddef0f3fe3408fb71fec23393f</gtr:id><gtr:otherNames>Haber N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1746-630X</gtr:issn><gtr:outcomeId>56c5b7cd87fe16.91927863</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>240BA6FC-60CD-41A1-B929-DC21462CBE0D</gtr:id><gtr:title>European AIDS Clinical Society Standard of Care meeting on HIV and related coinfections: The Rome Statements.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21635c26d64629e5278fa0599226a2bc"><gtr:id>21635c26d64629e5278fa0599226a2bc</gtr:id><gtr:otherNames>Mussini C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>58c2959c6e6a63.16048358</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54C2CE11-14B0-4BE1-8150-091EC043327F</gtr:id><gtr:title>A phylotype-based analysis highlights the role of drug-naive HIV-positive individuals in the transmission of antiretroviral resistance in the UK.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc08391f270e071c476c7cde6ea98b68"><gtr:id>fc08391f270e071c476c7cde6ea98b68</gtr:id><gtr:otherNames>Mourad R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>58c297c4dc9106.04109907</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1728E5EE-1488-4779-AAD1-4E32E9A78317</gtr:id><gtr:title>The association between detected drug resistance mutations and CD4T-cell decline in HIV-positive individuals maintained on a failing treatment regimen.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6ee0191fadaa18fc24b6cf304cc55b06"><gtr:id>6ee0191fadaa18fc24b6cf304cc55b06</gtr:id><gtr:otherNames>Schultze A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>5a940e90ead9c2.06217252</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5AC630BC-413A-49E0-976A-36C0B978B85A</gtr:id><gtr:title>Natural history of HIV-control since seroconversion.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34e0981385f9ed651683ac74a8c32eb9"><gtr:id>34e0981385f9ed651683ac74a8c32eb9</gtr:id><gtr:otherNames>Madec Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_13071_21_23912979</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F8D7834-EC60-4238-9D65-AB51A9B71A6F</gtr:id><gtr:title>Characterisation of long-term non-progression of HIV-1 infection after seroconversion: a cohort study.</gtr:title><gtr:parentPublicationTitle>The lancet. HIV</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/88ca6a744cb967e6309c7f6a5e6afe4e"><gtr:id>88ca6a744cb967e6309c7f6a5e6afe4e</gtr:id><gtr:otherNames>van der Helm JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2352-3018</gtr:issn><gtr:outcomeId>56b1c98cb33859.64199234</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88FD5578-7C3A-428D-BADB-26F7DF7419DA</gtr:id><gtr:title>Persistence of HIV-1 transmitted drug resistance mutations.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f922cffe072fd13496e024ca3b4ee31f"><gtr:id>f922cffe072fd13496e024ca3b4ee31f</gtr:id><gtr:otherNames>Castro H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>pm_13071_21_23904291</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9EE32F2B-CB96-4DAF-97D3-5E81BF10236C</gtr:id><gtr:title>Inequalities by educational level in response to combination antiretroviral treatment and survival in HIV-positive men and women in Europe.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf99bd7955fdc3c153f0c234d0390216"><gtr:id>bf99bd7955fdc3c153f0c234d0390216</gtr:id><gtr:otherNames>Socio-economic Inequalities and HIV Working Group for Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in Euro-Coord</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5a941163d6dae9.68437051</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BFA9DD80-47E0-4571-93AE-78085838CC53</gtr:id><gtr:title>A tale of two countries: all-cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/282ae484e5c075253c677437743d1964"><gtr:id>282ae484e5c075253c677437743d1964</gtr:id><gtr:otherNames>Patterson S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>5a940e9181f8a7.11258903</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56F92C13-3D0A-4EA0-B4F8-47599C8E4A5A</gtr:id><gtr:title>Joint estimation of CD4+ cell progression and survival in untreated individuals with HIV-1 infection.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cdaf6f773b6a94d33c43e43a06821d61"><gtr:id>cdaf6f773b6a94d33c43e43a06821d61</gtr:id><gtr:otherNames>Mangal TD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5a941167761413.65374587</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22AD21D4-2682-4054-88B6-12ED7437AD87</gtr:id><gtr:title>Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d9083cf7f259ffaa29a5f78c0453b86"><gtr:id>3d9083cf7f259ffaa29a5f78c0453b86</gtr:id><gtr:otherNames>Baxter JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>56d5ca78382313.93015478</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A725CFE-309E-478E-8891-6AFCE6F7734B</gtr:id><gtr:title>The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort study.</gtr:title><gtr:parentPublicationTitle>CMAJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/20fdc530f0acf18f9aa6993e7cf09af6"><gtr:id>20fdc530f0acf18f9aa6993e7cf09af6</gtr:id><gtr:otherNames>Klein MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2291-0026</gtr:issn><gtr:outcomeId>56d5ca7873b388.59186536</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74540A50-6120-46C6-9EA1-12DA07B2199F</gtr:id><gtr:title>Development and future directions for the Joint United Nations Programme on HIV/AIDS estimates.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/05d66814e63753d82ca16869a696b2ed"><gtr:id>05d66814e63753d82ca16869a696b2ed</gtr:id><gtr:otherNames>Case KK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>56b1c98d1f4091.57863245</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3060F45F-A982-4400-B99E-994777F3EDDB</gtr:id><gtr:title>Relating HIV testing patterns in Poland to risky and protective behaviour.</gtr:title><gtr:parentPublicationTitle>AIDS care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e9ec63e74088d1c42dff5d3e313ecbe8"><gtr:id>e9ec63e74088d1c42dff5d3e313ecbe8</gtr:id><gtr:otherNames>Rosinska M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0954-0121</gtr:issn><gtr:outcomeId>56c5b7cd5cc499.71437350</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C4F0AB70-38AA-48F5-86C8-6F53F4764BE7</gtr:id><gtr:title>The Human Immunodeficiency Virus Continuum of Care in European Union Countries in 2013: Data and Challenges.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6d5b74fcf8f84c4c25aa3a8d9745f70"><gtr:id>b6d5b74fcf8f84c4c25aa3a8d9745f70</gtr:id><gtr:otherNames>Gourlay A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>5a9411640e3ba1.65719372</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54FBBB34-CB0B-460B-9555-9BDDF199D2ED</gtr:id><gtr:title>A qualitative study exploring the social and environmental context of recently acquired HIV infection among men who have sex with men in South-East England.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b6d5b74fcf8f84c4c25aa3a8d9745f70"><gtr:id>b6d5b74fcf8f84c4c25aa3a8d9745f70</gtr:id><gtr:otherNames>Gourlay A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>5a9411662c5ae6.79652780</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55140B05-5690-4AFA-8F6A-411BA8232FE7</gtr:id><gtr:title>Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9859179eab8d2f5d7df659dae68e5864"><gtr:id>9859179eab8d2f5d7df659dae68e5864</gtr:id><gtr:otherNames>Dolling DI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>pm_13071_21_23711895</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99E4C3C1-BC6B-4823-89DD-03120EA1E29B</gtr:id><gtr:title>The increasing genetic diversity of HIV-1 in the UK, 2002-2010.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ee525c2e3a0983da94ca3d109d1764b"><gtr:id>9ee525c2e3a0983da94ca3d109d1764b</gtr:id><gtr:otherNames>UK Collaborative Group on HIV Drug Resistance</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>545d04f731ac75.25511617</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>492685F3-0BC6-45D5-AA47-5B2B9D8611DD</gtr:id><gtr:title>A systematic review of definitions of extreme phenotypes of HIV control and progression.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/028c877b2dbe31d6e55c00dfe30822ee"><gtr:id>028c877b2dbe31d6e55c00dfe30822ee</gtr:id><gtr:otherNames>Gurdasani D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>544e295801f582.02627040</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87A82EFB-60C3-424E-AB64-4AB6AB2872C6</gtr:id><gtr:title>Virological Blips and Predictors of Post Treatment Viral Control After Stopping ART Started in Primary HIV Infection.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d9df44b6c9d4866d2f12eaaf87afc68"><gtr:id>2d9df44b6c9d4866d2f12eaaf87afc68</gtr:id><gtr:otherNames>Fidler S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>58c2959dab19b6.26628315</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A85D8113-8CAB-41CE-A3B9-F8BF93CB4B30</gtr:id><gtr:title>The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8352078ca98c41558105c7dc74704bb4"><gtr:id>8352078ca98c41558105c7dc74704bb4</gtr:id><gtr:otherNames>Pantazis N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>56c5b7cc414cd7.12385846</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>78BA887D-E4B7-4375-B276-F3EA873E8CA1</gtr:id><gtr:title>Clinical Status of Adolescents with Perinatal HIV at Transfer to Adult Care in the UK/Ireland.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d66b4398b1376bf2dece8528b69a272c"><gtr:id>d66b4398b1376bf2dece8528b69a272c</gtr:id><gtr:otherNames>Collins IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>5a940e92a1bcb2.19600611</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>608139D6-FA72-4EC9-9F56-A12E44F8430F</gtr:id><gtr:title>Using incidence assays within the context of the recent infections testing algorithm.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/48b41a7bf26cc5bdd6192b93f1e3b8e5"><gtr:id>48b41a7bf26cc5bdd6192b93f1e3b8e5</gtr:id><gtr:otherNames>Simmons R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>544e2959118816.36479367</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>872A04AC-E956-48F6-BD58-6B633C0A1EF6</gtr:id><gtr:title>Intercontinental dispersal of HIV-1 subtype B associated with transmission among men who have sex with men in Japan.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b9c01792a7d27fee5dc4b30b44344ea"><gtr:id>0b9c01792a7d27fee5dc4b30b44344ea</gtr:id><gtr:otherNames>Takebe Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>545d04f805d445.26854478</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C80FBC78-7470-4BAB-83E1-33DB622A596C</gtr:id><gtr:title>Towards standardized definitions for monitoring the continuum of HIV care in Europe.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b24ec7623b969cce808560f0704b0bbf"><gtr:id>b24ec7623b969cce808560f0704b0bbf</gtr:id><gtr:otherNames>Gourlay AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5a941164a0e529.13247647</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3AFB51E-51D9-4C46-BB36-E92E4D33C201</gtr:id><gtr:title>Long-term mortality in HIV-positive individuals virally suppressed for &amp;gt;3 years with incomplete CD4 recovery.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5754a6c189699f93dc0d4ebf6bd186d"><gtr:id>a5754a6c189699f93dc0d4ebf6bd186d</gtr:id><gtr:otherNames>Engsig FN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>544e2958675700.63209673</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>718E7068-3305-43CF-A32C-1DB6CA91B60C</gtr:id><gtr:title>Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-na&amp;iuml;ve patients.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1097e87ec24072923b7411737a790c9b"><gtr:id>1097e87ec24072923b7411737a790c9b</gtr:id><gtr:otherNames>Bouteloup V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>58c297c2afcaf3.54319259</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EBC117EF-4539-4747-8035-09ADA63E531C</gtr:id><gtr:title>Phylogenetic analyses reveal HIV-1 infections between men misclassified as heterosexual transmissions.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d0e4078101e2913852def3cc79eff29"><gtr:id>0d0e4078101e2913852def3cc79eff29</gtr:id><gtr:otherNames>Hu? S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>545d04f7d505d1.63553205</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4EEF8D14-1570-47DF-AE1D-D77ACD85D860</gtr:id><gtr:title>Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study.</gtr:title><gtr:parentPublicationTitle>The lancet. HIV</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/95ce060460afd7ecfb47de3afe705795"><gtr:id>95ce060460afd7ecfb47de3afe705795</gtr:id><gtr:otherNames>O'Connor J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2352-3018</gtr:issn><gtr:outcomeId>5a940e915870f1.43880749</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8E24143-607F-430E-9708-40C8AEEF464A</gtr:id><gtr:title>HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/563fd32d33db3b363f5c403619e78b9d"><gtr:id>563fd32d33db3b363f5c403619e78b9d</gtr:id><gtr:otherNames>El Bouzidi K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>58c297c1e33590.56636622</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF2F758E-46E8-49DF-9C0E-BD889493462A</gtr:id><gtr:title>Novel HIV-1 recombinants spreading across multiple risk groups in the United Kingdom: the identification and phylogeography of Circulating Recombinant Form (CRF) 50_A1D.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/737902126252eeca216b14d33630e096"><gtr:id>737902126252eeca216b14d33630e096</gtr:id><gtr:otherNames>Foster GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>545d04f7ab8eb4.68352772</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>401DC047-4125-4D59-A9E3-26F7CAE98D8B</gtr:id><gtr:title>Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4063af6dad22e62292f5b01da1f6d12d"><gtr:id>4063af6dad22e62292f5b01da1f6d12d</gtr:id><gtr:otherNames>Tostevin A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>58c297c324ba02.43450135</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EEAE587D-1534-40F3-9329-46FAFC9E7CE4</gtr:id><gtr:title>A Direct Comparison of Two Densely Sampled HIV Epidemics: The UK and Switzerland.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/372c212584ac2efb0a65f6beb91c0c0d"><gtr:id>372c212584ac2efb0a65f6beb91c0c0d</gtr:id><gtr:otherNames>Ragonnet-Cronin ML</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>58c297c2529c64.52682418</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32844FD9-D93F-414C-BD94-4E376E248CCF</gtr:id><gtr:title>The Impact of HCV Infection Duration on HIV Disease Progression and Response to cART amongst HIV Seroconverters in the UK.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6aa64ae486428fd99ca0a334b2bef924"><gtr:id>6aa64ae486428fd99ca0a334b2bef924</gtr:id><gtr:otherNames>Inshaw J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56c5b7cb8d0428.75500848</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>78E83030-C3AB-43F6-8076-E7E6BBA9F551</gtr:id><gtr:title>Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c80f3aef44abde16148ceba1e325c6cd"><gtr:id>c80f3aef44abde16148ceba1e325c6cd</gtr:id><gtr:otherNames>Migrant Health Working Group for the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>5a940e92c87149.46899251</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D9BE617-3201-4196-919D-B12F49034CC0</gtr:id><gtr:title>Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.</gtr:title><gtr:parentPublicationTitle>The lancet. HIV</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3bb7550f609baa2a9b35e3e68f3c7c7"><gtr:id>d3bb7550f609baa2a9b35e3e68f3c7c7</gtr:id><gtr:otherNames>Lodi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2352-3018</gtr:issn><gtr:outcomeId>58c297c48e98c8.02156161</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E2BA16D5-6F9D-4317-8151-53FB315A911B</gtr:id><gtr:title>HIV Incidence Estimates Using the Limiting Antigen Avidity EIA Assay at Testing Sites in Kiev City, Ukraine: 2013-2014.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/48b41a7bf26cc5bdd6192b93f1e3b8e5"><gtr:id>48b41a7bf26cc5bdd6192b93f1e3b8e5</gtr:id><gtr:otherNames>Simmons R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>58c2959d3ee575.00908978</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E2E5A59F-C911-453A-A82B-B33DF14DCD7A</gtr:id><gtr:title>Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c46f2d9ffe46edb4c77cc56e89bb86f5"><gtr:id>c46f2d9ffe46edb4c77cc56e89bb86f5</gtr:id><gtr:otherNames>TenoRes Study Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>58c297c34b1c54.17691136</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88814099-54D9-466E-BE50-0DA1DFDA5BC4</gtr:id><gtr:title>Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013.</gtr:title><gtr:parentPublicationTitle>Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3354b898dc3fab8f4c151b37b015c5bf"><gtr:id>3354b898dc3fab8f4c151b37b015c5bf</gtr:id><gtr:otherNames>Late presenters working group in COHERE in EuroCoord</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1025-496X</gtr:issn><gtr:outcomeId>58c297c41b49f2.45090391</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A3B2EBC-F0F2-482E-8E14-287DA3299434</gtr:id><gtr:title>HIV incidence in the Estonian population in 2013 determined using the HIV-1 limiting antigen avidity assay.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aabe33d26946c242f04fe63fc14b914c"><gtr:id>aabe33d26946c242f04fe63fc14b914c</gtr:id><gtr:otherNames>Soodla P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>5a9411679b37b5.04635656</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E29214C-38C9-4937-926D-905658E79EE3</gtr:id><gtr:title>Role of HIV infection duration and CD4 cell level at initiation of combination anti-retroviral therapy on risk of failure.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3bb7550f609baa2a9b35e3e68f3c7c7"><gtr:id>d3bb7550f609baa2a9b35e3e68f3c7c7</gtr:id><gtr:otherNames>Lodi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>544e2b17cf5db7.95831619</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48D5F347-3C33-484B-9259-C19615995EA7</gtr:id><gtr:title>A Phylogenetic Analysis of HIV-1 Sequences in Kiev: Findings among Key Populations.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2623e5ec70f8f3bd35e4b18e14572124"><gtr:id>2623e5ec70f8f3bd35e4b18e14572124</gtr:id><gtr:otherNames>Fearnhill E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>5a941164c9a6d3.67515120</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8B21622-709F-4430-ACB1-F8BCE4CABC6A</gtr:id><gtr:title>Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57c30723062483d637e0ebc9fff97497"><gtr:id>57c30723062483d637e0ebc9fff97497</gtr:id><gtr:otherNames>Waters L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>pm_13071_21_23653911</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8D6A3ED-1C79-4862-90B7-9016F0A3BE9E</gtr:id><gtr:title>The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort.</gtr:title><gtr:parentPublicationTitle>The Journal of infection</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0f911b1a5eb21f1fd0ce082a070f9f8"><gtr:id>c0f911b1a5eb21f1fd0ce082a070f9f8</gtr:id><gtr:otherNames>Bulteel N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0163-4453</gtr:issn><gtr:outcomeId>545d04f7843ed4.24477094</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FB19901-85A1-4174-A715-CF905D478D11</gtr:id><gtr:title>Beyond viral suppression of HIV - the new quality of life frontier.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3ebc5b07038ad4b4a0411af80e03197"><gtr:id>f3ebc5b07038ad4b4a0411af80e03197</gtr:id><gtr:otherNames>Lazarus JV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>5a94116363cdc7.66770338</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18C0F95C-8FA2-4133-9381-71E8DB615DF0</gtr:id><gtr:title>Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0bfb861f5cf1f76dc091b8fcd6f34e9"><gtr:id>e0bfb861f5cf1f76dc091b8fcd6f34e9</gtr:id><gtr:otherNames>Antiretroviral Therapy Cohort Collaboration (ART-CC)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>58c297c44fdf80.27591637</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CAB19FA7-A901-405F-B44D-675682DE1742</gtr:id><gtr:title>Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/991cf92a3d257a570ad0cfac152b2d53"><gtr:id>991cf92a3d257a570ad0cfac152b2d53</gtr:id><gtr:otherNames>May MT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>544e2958d97be1.93398610</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F21E80A-F51E-4F98-8813-F9EF6445722A</gtr:id><gtr:title>Brief Report: Enhanced Normalization of CD4/CD8 Ratio With Earlier Antiretroviral Therapy at Primary HIV Infection.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5396838a64e07f0e26ca612ba419eddb"><gtr:id>5396838a64e07f0e26ca612ba419eddb</gtr:id><gtr:otherNames>Thornhill J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>58c2959d0a29a0.38595687</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F442F28-7578-4AF9-A194-58F5037A231D</gtr:id><gtr:title>Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1ce1019afdb46421f329d5589108d95"><gtr:id>f1ce1019afdb46421f329d5589108d95</gtr:id><gtr:otherNames>St?hr W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>58c2959c320fa5.95287326</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A1020F7F-9753-47D9-9261-53938A1EA8EF</gtr:id><gtr:title>Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66880df30e269a3e929a7c58fe3ba252"><gtr:id>66880df30e269a3e929a7c58fe3ba252</gtr:id><gtr:otherNames>Santoro MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>pm_13071_21_23668660</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71222522-559A-4CCE-B5BD-C6F71E08A307</gtr:id><gtr:title>Clinical characteristics and outcomes of HIV-associated immune complex kidney disease.</gtr:title><gtr:parentPublicationTitle>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c926053cd3c7f247fa364994945f7609"><gtr:id>c926053cd3c7f247fa364994945f7609</gtr:id><gtr:otherNames>Booth JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0931-0509</gtr:issn><gtr:outcomeId>58c297c3b1fb67.21383419</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2229BCBD-DDC1-4D45-B4DA-4C938280882A</gtr:id><gtr:title>No Evidence That HIV-1 Subtype C Infection Compromises the Efficacy of Tenofovir-Containing Regimens: Cohort Study in the United Kingdom.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5bf35c02b678f95ce3832966880e6f44"><gtr:id>5bf35c02b678f95ce3832966880e6f44</gtr:id><gtr:otherNames>White E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>58c297c2210ca8.71519369</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FDEB37EC-6FA2-44BE-BB08-1D50E316F3B7</gtr:id><gtr:title>An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ffadb08aae12c5867ce7c13b7fc78833"><gtr:id>ffadb08aae12c5867ce7c13b7fc78833</gtr:id><gtr:otherNames>Olson AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>544e29582ff770.48424350</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC7D84C7-B9CC-4F83-8436-40810865037F</gtr:id><gtr:title>The contribution of viral genotype to plasma viral set-point in HIV infection.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8a6f6588856978d76ed6abeb8216566a"><gtr:id>8a6f6588856978d76ed6abeb8216566a</gtr:id><gtr:otherNames>Hodcroft E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>545d04f75c5938.35462143</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D37E480-2CBE-40C4-8E90-8E1A07AC54CA</gtr:id><gtr:title>Subtype-specific differences in the development of accessory mutations associated with high-level resistance to HIV-1 nucleoside reverse transcriptase inhibitors.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e7ffd30d3d558be5c0122ed5a8f57f0"><gtr:id>8e7ffd30d3d558be5c0122ed5a8f57f0</gtr:id><gtr:otherNames>Koning FA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>pm_13071_21_23386260</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0EAC6CE-F41E-4705-BB2B-AA53D86EFEE0</gtr:id><gtr:title>Host, disease, and antiretroviral factors are associated with normalization of the CD4:CD8 ratio after initiating antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>The Journal of allergy and clinical immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e11668afe47c6624eb66cf3d5932f65a"><gtr:id>e11668afe47c6624eb66cf3d5932f65a</gtr:id><gtr:otherNames>Winston A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0091-6749</gtr:issn><gtr:outcomeId>58c297c59b68b2.94891476</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60442FDB-BAAD-40F0-9691-7171BD50A5C0</gtr:id><gtr:title>Temporal trends of transmitted HIV drug resistance in a multinational seroconversion cohort.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/67c7968f703f22a381448d17c15e5ea8"><gtr:id>67c7968f703f22a381448d17c15e5ea8</gtr:id><gtr:otherNames>Olson A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5a941167c22f52.08081202</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EADD5612-62CF-42D1-8843-02ACB0B47C4B</gtr:id><gtr:title>The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf9fce5f75d358dfd61d4fb5eb850393"><gtr:id>bf9fce5f75d358dfd61d4fb5eb850393</gtr:id><gtr:otherNames>Mackie NE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_13071_21_24157905</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D79F1F0A-A05A-4813-84AA-D3EA90DCA5F0</gtr:id><gtr:title>British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/82f013a0987af324b617005307846005"><gtr:id>82f013a0987af324b617005307846005</gtr:id><gtr:otherNames>Churchill D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>58c297c2e48306.32344361</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>751582FB-5BE8-4D10-BA36-33635B8CCA43</gtr:id><gtr:title>Hepatitis B, hepatitis C, and mortality among HIV-positive individuals.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8a4a95ddd298f28da17be0ed8ee69b3d"><gtr:id>8a4a95ddd298f28da17be0ed8ee69b3d</gtr:id><gtr:otherNames>Thornton AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5a940e90b19133.09048338</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B9CDC11-F236-4AF2-924C-C5543EDFD070</gtr:id><gtr:title>Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d3bb7550f609baa2a9b35e3e68f3c7c7"><gtr:id>d3bb7550f609baa2a9b35e3e68f3c7c7</gtr:id><gtr:otherNames>Lodi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5a941167f1f7b2.30223222</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF275541-A994-4F9C-BF8B-12AB31520CB9</gtr:id><gtr:title>Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91e9e79ddc1ff12466df8f0af4fb3c40"><gtr:id>91e9e79ddc1ff12466df8f0af4fb3c40</gtr:id><gtr:otherNames>Caniglia EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>5a941168296415.98924005</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A66355EF-A576-4C6E-9A13-DFF040E3206C</gtr:id><gtr:title>HIV Testing and Diagnosis Rates in Kiev, Ukraine: April 2013-March 2014.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/48b41a7bf26cc5bdd6192b93f1e3b8e5"><gtr:id>48b41a7bf26cc5bdd6192b93f1e3b8e5</gtr:id><gtr:otherNames>Simmons R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56c5b7cc083876.57780238</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66BD5B5E-3408-4A7E-94BD-141C11993A29</gtr:id><gtr:title>Evaluation of rapid progressors in HIV infection as an extreme phenotype.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ffadb08aae12c5867ce7c13b7fc78833"><gtr:id>ffadb08aae12c5867ce7c13b7fc78833</gtr:id><gtr:otherNames>Olson AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>544e2958a66204.86238277</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UU_12023/15</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>9A8BEDCC-D902-4C9A-8CCF-C974265EA3FB</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.4  Surveillance and distribution</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>